Supriya Lifescience share news and announcements
NSE: SUPRIYABSE: 543434Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹836.25.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹6,588 Cr733rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 33.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 27 May 2026
- 5.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.12%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 18.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 21.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 27 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,62,92342.0% delivered
Supriya Lifescience analyst meets
145 filed, newest first. Page 2 of 3.
Jul 2024
11 Jul · Analysts
2 Jul · Analysts
Jun 2024
17 Jun · Analysts
7 Jun · Analysts
May 2024
21 May · Analysts
Apr 2024
25 Apr · Analysts
19 Apr · Analysts
5 Apr · Analysts
Mar 2024
21 Mar · Analysts
14 Mar · Analysts
6 Mar · Analysts
6 Mar · Analysts
5 Mar · Analysts
5 Mar · Analysts
Feb 2024
23 Feb · Analysts
20 Feb · Analysts
Jan 2024
31 Jan · Analysts
Dec 2023
26 Dec · Analysts
Nov 2023
28 Nov · Analysts
17 Nov · Analysts
Oct 2023
27 Oct · Analysts
Sep 2023
26 Sep · Analysts
20 Sep · Analysts
14 Sep · Analysts
13 Sep · Analysts
11 Sep · Analysts
8 Sep · Analysts
Aug 2023
24 Aug · Analysts
17 Aug · Analysts
Jul 2023
28 Jul · Analysts
1 Jul · Analysts
Jun 2023
28 Jun · Analysts
22 Jun · Analysts
May 2023
20 May · Analysts
Apr 2023
13 Apr · Analysts
7 Apr · Analysts
Mar 2023
27 Mar · Analysts
16 Mar · Analysts
13 Mar · Analysts
9 Mar · Analysts
Feb 2023
9 Feb · Analysts
Dec 2022
30 Dec · Analysts
Nov 2022